Author

Abinash Patnaik

Observed name: A. Patnaik

Institutions: Gujarat Cancer & Research Institute, Siksha O Anusandhan University, Institute of Medical Sciences and Sum Hospital, B.J. Medical College

Observed institutions: Gujarat Cancer & Research Institute, Siksha O Anusandhan University, Sriram Chandra Bhanja Medical College Hospital, Institute of Medical Sciences and Sum Hospital, B.J. Medical College

ORCID: 0000-0003-1437-6706

Observed ORCID: 0000-0003-1437-6706

OpenAlex ID: A5009824824

Differentiating flare and infection in febrile lupus patients: Derivation and validation of a calculator for resource constrained settings

2022 · Pankti Mehta, Komal Singh, et al. · Lupus · 14

Emerging role of immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma

2025 · Goutham Sunny, Abinash Patnaik, et al. · International Journal of Molecular and Immuno Oncology · 1

Six-Weekly Low-Dose Nivolumab Combined with Oral Triple Metronomic Chemotherapy for Advanced Cancers of the Head and Neck: An Open-Label, Prospective, Single-Institution Experience from Eastern India

2026 · Santosh Kumar Swain, Soumya Surath Panda, et al. · Research Square

Primary Leiomyosarcoma of the Urinary Bladder in a Middle-Aged Woman: A Case Report with Review of Previously Published Cases

2026 · Kartik Kadia, Lalatendu Moharana, et al. · Research Square

Clinicopathologic profile and comparative performance of limited next-generation sequencing and quantitative/real-time polymerase chain reaction for detection of RAS/RAF mutations in metastatic colorectal cancer

2026 · Ayush Dubey, Subhashree Subhasmita Dash, et al. · Research Square

Navigating Recurrence in Clear Cell Renal Cell Carcinoma after Adjuvant Immunotherapy

2026 · Goutham Sunny, Shrikanth Ravichandran, et al. · Journal of Kidney Cancer and VHL

Choosing Between Atezolizumab-Bevacizumab and STRIDE in First-Line Advanced Hepatocellular Carcinoma

2026 · Praloy Basu, Rajan Yadav, et al. · International Journal of Science and Research (IJSR)

Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year Retrospective Audit

2026 · Goutham Reddy Ramidi, Rajan Yadav, et al. · Cureus

Gut microbiome modulates carcinogenesis, immunotherapy efficacy and treatment resistance

2026 · Goutham Sunny, Abinash Patnaik, et al. · Discover Medicine

Low-Dose Metronomic Chemotherapy With Fixed Low-Dose Nivolumab for Recurrent Cervical Cancer After Radiotherapy: Experience From Routine Clinical Practice

2026 · Goutham Reddy Ramidi, Rajan Yadav, et al. · Cureus

329P Second-line chemotherapy outcomes in malignant pleural mesothelioma after platinum–pemetrexed: 5-year real-world experience from a public cancer centre in India

2026 · R. Yadav, H.P. Panchal, et al. · ESMO Open

Navigating resistance to immunotherapy in head-and-neck cancers: Mechanism and novel approaches

2025 · Abinash Patnaik, Goutham Sunny, et al. · International Journal of Molecular and Immuno Oncology

Neoadjuvant chemotherapy followed by surgery versus definitive chemoradiotherapy in locally advanced head-and-neck cancer

2025 · Abinash Patnaik, Yuganshu Gupta, et al. · International Journal of Molecular and Immuno Oncology

Works count: 13

Citation count: 15

H-index: 1

I10-index: 1